<DOC>
	<DOCNO>NCT00191555</DOCNO>
	<brief_summary>The objective study demonstrate benefit switch chronic schizophrenic patient conventional antipsychotic olanzapine term efficacy , neurological safety patient 's outcome .</brief_summary>
	<brief_title>Efficacy Study Switching Stabilized Schizophrenic Patients From Conventional Atypical Antipsychotic Treatment</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Haloperidol</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<mesh_term>Haloperidol decanoate</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<criteria>Schizophrenic patient meeting DSMIV diagnostic criterion one year ago treat antipsychotic least 1 year . Outpatient ( patient admit hospital social logistic reason ) . Patient receive stable dose conventional antipsychotic least 8 week visit 1 . Patient present PANSS score equal great 49 Visit 2 . Patient consider investigator possible candidate switch , owe inadequate efficacy poor safety current treatment . Patient present schizophreniform schizoaffective disorder accord DSMIV diagnostic criterion , disorder Axis I DSMIV , disorder Axis II ( limit personality ) , substance dependence substance abuse . Administration atypical antipsychotic drug 8 week precede V1 . History resistance antipsychotic drug Hospitalization psychiatric unit psychiatric emergency department within 8 week precede begin study . Presence serious unstable disease , fatal outcome hospitalization intensive care unit , foreseeable within period 6 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2006</verification_date>
</DOC>